Insights - Shares of Achillion Pharmaceuticals (ACHN) are up another 60% on Tuesday, adding to gains that coincided with Monday’s acquisition of fellow early HCV competitor, Idenix Pharmaceutical (IDIX). The stock is up 125% for … Continue Reading
Read NowInsights - The announcement that Merck (MRK) plans to acquire Idenix Pharmaceuticals (IDIX) for $3.85 billion, or $24.50 per share, is having a ripple effect on the … Continue Reading
Read NowRecap - First, we’re hosting a networking event for healthcare investors, traders, and analysts on June 17th – details and RSVP here. It’s all about dialog, an investor’s best friend when you’ve … Continue Reading
Read NowInsights - In an SEC filing on Wednesday, Retrophin (RTRX) CEO Martin Shkreli reported the sale of 292,400 shares of RTRX common stock worth $4.4 million dollars last Friday, nearly 10% … Continue Reading
Read NowInsights - Prosensa (RNA) will seek FDA and European approval for drisapersen, its drug candidate for Duchenne Muscular Dystrophy, following correspondence with the US regulatory body and what appears … Continue Reading
Read NowInterviews - A recent FDA bulletin puts the success rate of Phase II clinical trials at just 18%, 50% in Phase III, citing insufficient efficacy and safety concerns as the … Continue Reading
Read NowRecap - These trades aren’t over yet, and you can catch up on the fundamental theses at PropThink.com. Below, our weekly recap. Shares of Biodelivery Sciences (BDSI) came close to … Continue Reading
Read Now
